ESC cardiologists 'intrigued' by novel approach to heart failure

January 30, 2012

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure1. In the "hypothesis generating" study, ursodeoxycholic acid (UDCA) delivered significant improvements in peak post ischemic blood flow in the arm, a trend for improvement in peak post ischemic blood flow in the leg, but failed to show benefits in exercise capacity and several inflammatory markers. Despite such conflicting data, ESC spokespersons believe that further exploration of UCDA is now justified in larger populations of heart failure patients.

"Although the study failed on two out of three counts , the observed improvements in post ischemic arm and leg make it highly unlikely such findings would have occurred purely by chance," says Professor Kenneth Dickstein, an ESC spokesperson. "The results are enough to pique real interest and suggest the approach has the potential to offer another string to our bow for improving heart failure symptoms."

It is also noteworthy, adds Dickstein from the University of Bergen (Stavanger University Hospital, Norway), that JACC felt the study to be of sufficient merit to commission an editorial2.

The theory underlying the use of UDCA (a commonly used in the treatment of cholestatic ) centres on the finding that abdominal congestion (caused by heart failure) leads to increased gut permeability, allowing produced by to enter the circulation. The increased levels of proinflammatory cytokines can then further exacerbate symptoms of heart failure. UDCA is able to form a complex ("mixed micelles") around a component of the cell-wall of the gram-negative bacteria (lipopolysaccharide), thereby decreasing levels of proinflammatory cytokines and offering the potential to improve peripheral blood flow and ultimately increase exercise tolerance.

In the last 10 to 15 years studies have explored modifying inflammation in (through anti-inflammatory agents, antibiotics and statins), but all have proved neutral or in some cases even resulted in worse outcomes for patients.

In the current prospective double-blind, cross-over study, Stephan von Haehling, from the Charité Medical School (Berlin, Germany), and colleagues from Poland, UK, Austria and Italy, assessed the effects of UDCA on and in 17 chronic heart failure patients who received 500 mg UDCA twice daily for four weeks, followed by placebo for another four weeks. Results showed that in comparison with placebo, UDCA significantly improved peak post-ischemic blood flow in the arm (p=0.038), and showed a trend for improved peak blood flow in the leg (p=0.079). No change, however, occurred in the six-minute walk test and for New York Heart Association functional class, and furthermore, levels of tumour necrosis factor a and interleukin-6 remained unchanged.

"One difficulty is that the UDCA hypothesis follows a precise pathway, and the results fail to demonstrate each step of the pathway, i.e. show that improvements in peripheral blood flow translate into improvements in the functional capacity measured by the six minute walk test", says Professor Aldo Maggioni, an ESC spokesperson, from the Centre of the Italian Association of Hospital Cardiologists (Florence, Italy). Furthermore, he adds, even improvements in peripheral blood flow were not equal in the arms and legs.

"The cross over design offers a real strength of the study since it allows patients to act as their own controls, but, the small number of patients involved makes statistical analysis unreliable," says Maggioni.

Any future studies undertaken, says Dickstein, will need to involve larger cohorts of patients. "One big question for me is whether four weeks of treatment is sufficient to produce significant effects. This begs the question of whether higher doses and longer durations of treatment might have produced clearer cut answers," he adds.

Recent registries showing a 5 to 8% annual mortality for chronic heart failure patients underline the urgent need for new treatments in addition to the standard ACE inhibitors, ARBs, beta blockers, aldosterone blockers and devices (implantable cardioverter defibrillators and cardiac resynchronisation therapy). "Since UDCA doesn't involve any of the known mechanisms adding this approach to the standard treatments might result in incremental gains," says Maggioni.

What's undisputed is that UDCA seems to have the ability to fire the imagination. "Part of the appeal of the concept is that it's so intuitively attractive. It provides a biologically plausible hypothesis that's really easy for everyone to understand," says Dickstein.

Explore further: Bear bile chemical could help keep hearts in rhythm

More information: 1. S. von Haehling, J. C. Schefold, E.A. Jankowska, et al. Ursodeoxycholic Acid in Patients With Chronic Heart Failure: A double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol February 7 2012;59:585.

2. J.M. McCabe, J.R. Teerlink, et al. Bile Salts for the Treatment of Heart Failure: Out on a limb for a gut feeling? Ibid, pp593-4.

Related Stories

Bear bile chemical could help keep hearts in rhythm

August 2, 2011
A synthesised compound which is also found in bear bile could help prevent disturbances in the heart's normal rhythm, according to research published today in the journal Hepatology by a team from Imperial College London.

Not faster, but longer -- new drug changes beat in treating heart failure

August 19, 2011
A new drug which offers a radically different approach to treating certain types of heart failure has been shown to improve cardiac function in heart failure patients in its first clinical trials.

ESC pilot registry in heart failure reflects improvement in chronic disease

August 30, 2011
With the increased prevalence of chronic heart failure (HF), there is a concomitant increase in the number of related hospitalisations; as chronic HF progresses, the risk of acute exacerbation increases.

Recommended for you

Laser device placed on the heart identifies insufficient oxygenation better than other measures

September 20, 2017
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital ...

Metabolism switch signals end for healing hearts

September 19, 2017
Researchers have identified the process that shuts down the human heart's ability to heal itself, and are now searching for a drug to reverse it.

Beta blockers not needed after heart attack if other medications taken

September 18, 2017
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge ...

Which single behavior best prevents high blood pressure?

September 15, 2017
(HealthDay)—You probably already know that certain healthy lifestyle behaviors can reduce your risk of developing high blood pressure, but is any one behavior more important than the others?

RESPECT trial shows closing a small hole in heart may protect against recurrent stroke

September 13, 2017
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial ...

Study shows so-called 'healthy obesity' is harmful to cardiovascular health

September 11, 2017
Clinicians are being warned not to ignore the increased cardiovascular health risks of those who are classed as either 'healthy obese' or deemed to be 'normal weight' but have metabolic abnormalities such as diabetes.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Sepp
not rated yet Feb 02, 2012
I wonder why no one is studying high-dose intravenous ascorbic acid for the same indication. It is almost certain to do better than the substance researched here. But then ... it isn't really a pharmaceutical product that a lot of money can be made of. It's "merely" a vitamin!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.